Genmab — Februar 2018
-
-
så kom warrents
-
65,419stk
-
- 220 shares at DKK 40.41,
-- 1,800 shares at DKK 68.65,
-- 3,625 shares at DKK 80.55,
-- 350 shares at DKK 210,
-- 250 shares at DKK 220.40,
-- 18,813 shares at DKK 225.90,
-- 200 shares at DKK 231.50,
-- 1,250 shares at DKK 234,
-- 1,250 shares at DKK 246,
-- 21,535 shares at DKK 254,
-- 6,850 shares at DKK 272,
-- 5,188 shares at DKK 337.40,
-- 88 shares at DKK 466.20, and
-- 4,000 shares at DKK 939.50.
- 220 shares at DKK 40.41,
-
Proceeds to the company are approximately DKK 18.3 million. The increase
corresponds to approx. 0.11% of the companys share capital. -
E L's link 9:47 is the reason why Celg drops 8% https://www.marketwatch.com/story/celgene-shares-drop-6-after-blunder-with-high-profile-drug-2018-02-28
-
CELG startede i 2014 med en licensaftale med upfront på ca $700 mln. Data rullede ind i 2015 og medio 2015 købte de Receptos og midlet ozanimod for $7,2 bn http://ir.celgene.com/releasedetail.cfm?ReleaseID=922090 Nu da fda ikke synes om bivirkningerne kan det hele være tabt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind